Back to Results
First PageMeta Content
Immunosuppressants / Clinical research / Amgen / Etanercept / Rheumatoid arthritis / Tumor necrosis factor-alpha / Biologic / Disease-modifying antirheumatic drug / Placebo / Medicine / Health / Pharmacology


Open Document

File Size: 1,35 MB

Share Result on Facebook

City

Rockville / /

Company

Amgen / AUB 2003 Immunex Corporation / /

Event

FDA Phase / /

Facility

American College of Rheumatology / Rockville Pike / /

IndustryTerm

proposed introductory advertising / Final printed advertising / /

MedicalCondition

tumor necrosis factor receptor / polyarticular-course juvenile rheumatoid arthritis / inflammatory processes / ankylosing spondylitis / RA psoriatic arthritis / arthritis / rheumatoid arthritis / active arthritis / RA disease / tumor necrosis factor / normal inflammatory and immune responses / inflammation / psoriatic arthritis / /

Organization

HUMAN SERVICES Public Health Service / Food and Drug Administration / Clinical Trials Design and Analysis office of Therapeutics Research / Therapeutics Research and Review Center for Drug Evaluation and Research Page / M. Acting Director Division of Clinical Trials Design / American College of Rheumatology / Center for Drug Evaluation and Research / DEPARTMENT OF HEALTH / Center for Biologics Evaluation and Research / Pharmacokinetics After administration / /

Person

Patricia Keegan / Hunt / /

Position

Physician global assessment / Director / CLINICAL PHARMACOLOGY General / /

Product

SC / ENBREL / sulfasalazine / MTX tablets / Bacteriostatic Water for Injection / azathioprine / mannitol / Etanercept / 51O2 / /

ProvinceOrState

Maryland / California / /

Technology

alpha / Pharmacokinetics / http / html / recombinant DNA technology / PDF / /

SocialTag